Detalhe da pesquisa
1.
Familial Clonal Hematopoiesis in a Long Telomere Syndrome.
N Engl J Med
; 388(26): 2422-2433, 2023 Jun 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-37140166
2.
Association of PARP inhibitor treatment on the prevalence and progression of clonal hematopoiesis in patients with advanced prostate cancer.
Prostate
; 2024 Apr 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38641986
3.
Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC).
Br J Cancer
; 130(1): 53-62, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37980367
4.
Impact of piflufolastat F-18 PSMA PET imaging on clinical decision-making in prostate cancer across disease states: A retrospective review.
Prostate
; 83(9): 863-870, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36999911
5.
Clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with abiraterone with or without ongoing androgen deprivation therapy: A retrospective case-control study.
Prostate
; 83(13): 1279-1284, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37337669
6.
Clinical and molecular determinants of PSA response to bipolar androgen therapy in prostate cancer.
Prostate
; 83(9): 879-885, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36959766
7.
Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer.
Prostate
; 83(3): 227-236, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36382533
8.
A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide.
Prostate
; 83(4): 376-384, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36564933
9.
Bipolar Androgen Therapy Followed by Androgen Receptor Inhibition as Sequential Therapy for Prostate Cancer.
Oncologist
; 28(6): 465-473, 2023 06 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37027449
10.
Bipolar androgen therapy (BAT): A patient's guide.
Prostate
; 82(7): 753-762, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35357024
11.
Clinical and genomic features of SPOP-mutant prostate cancer.
Prostate
; 82(2): 260-268, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34783071
12.
Clinical and pathological features associated with circulating tumor DNA content in real-world patients with metastatic prostate cancer.
Prostate
; 82(7): 867-875, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35286728
13.
Association of B7-H3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancer.
Cancer
; 128(12): 2269-2280, 2022 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35333400
14.
Association between pathogenic germline mutations in BRCA2 and ATM and tumor-infiltrating lymphocytes in primary prostate cancer.
Cancer Immunol Immunother
; 71(4): 943-951, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-34533610
15.
Cooling inflammation while potentiating immune checkpoint inhibition: Enhancing the benefit-risk ratio of immuno-oncology therapy.
Proc Natl Acad Sci U S A
; 121(9): e2400431121, 2024 Feb 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38354255
16.
BRCA1/2 Reversion Mutations in Patients Treated with Poly ADP-Ribose Polymerase (PARP) Inhibitors or Platinum Agents.
Medicina (Kaunas)
; 58(12)2022 Dec 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36557020
17.
Genomic profiles and clinical outcomes in primary versus secondary metastatic hormone-sensitive prostate cancer.
Prostate
; 81(9): 572-579, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33955569
18.
Nivolumab plus ipilimumab, with or without enzalutamide, in AR-V7-expressing metastatic castration-resistant prostate cancer: A phase-2 nonrandomized clinical trial.
Prostate
; 81(6): 326-338, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33636027
19.
Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations.
Prostate
; 81(16): 1382-1389, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34516663
20.
Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer.
Prostate
; 81(7): 433-439, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33792945